MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24 | Market Closed - Börse Stuttgart 02:19:44 2024-06-28 pm EDT | ||
| 0.74 EUR | +1.37% |
|
| Current month | +32.14% | ||
| 1 month | +17.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.74 | +1.37% |
| 24-06-27 | 0.73 | +1.39% |
| 24-06-26 | 0.72 | 0.00% |
| 24-06-25 | 0.72 | -4.00% |
| 24-06-24 | 0.75 | +10.29% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:19 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME4N39 |
| ISIN | DE000ME4N394 |
| Date issued | 2023-12-05 |
| Strike | 410 $ |
| Maturity | 2024-09-20 (82 Days) |
| Parity | 100 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.84 € |
|---|---|
| Lowest since issue | 0.219 € |
| Spread | 0.01 € |
| Spread % | 1.45% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
